Volatile Stocks at NASDAQ: FireEye (NASDAQ:FEYE), Medidata Solutions Inc. (NASDAQ:MDSO), Gevo, Inc. (NASDAQ:GEVO), Celldex Therapeutics (NASDAQ:CLDX)

FireEye, Inc. (NASDAQ:FEYE), the leader in stopping today’s advanced cyber-attacks, on 10 April announced the release of the fifth annual Mandiant(R) M-Trends(R) report. FireEye Inc. (NASDAQ:FEYE) shares after opening at $50.33 moved to $50.76 on last trade day and at the end of the day closed at $46.76. Company price to sales ratio in past twelve months was calculated as 41.71 and price to cash ratio as 38.76. FireEye Inc. (NASDAQ:FEYE) showed a negative weekly performance of -4.24%.

Medidata Solutions (NASDAQ:MDSO) issued its quarterly earnings data on Tuesday. The company reported $0.11 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.16 by $0.05, AnalystRatings.Net reports. The company had revenue of $76.60 million for the quarter, compared to the consensus estimate of $79.50 million. Medidata Solutions Inc. (NASDAQ:MDSO) shares advanced 7.91% in last trading session and ended the day on $43.93. MDSO return on equity ratio is recorded as 8.80% and its return on assets is 4.20%. Medidata Solutions Inc. (NASDAQ:MDSO) yearly performance is 63.86%.

Gevo, Inc. (NASDAQ:GEVO) stock is trading lower on Wednesday after making big gains on Tuesday. The renewable biofuel developer soared earlier in the week after announcing Lufthansa will evaluate the company’s renewable jet fuel with the aim to approve its alcohol-to-jet fuel (ATJ) formula for commercial aviation use. Gevo, Inc. (NASDAQ:GEVO) shares moved down -7.63% in last trading session and was closed at $1.09, while trading in range of $1.04 – $1.23. Gevo, Inc. (NASDAQ:GEVO) year to date (YTD) performance is -23.78%.

On April 7, 2014, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of Celldex Therapeutics, Inc. (NASDAQ:CLDX), the Board adopted amended and restated by-laws to among other things replace with the plurality voting standard with a majority voting standard for uncontested elections of directors and eliminate the mandatory retirement age for directors. Celldex Therapeutics, Inc. (NASDAQ:CLDX) weekly performance is 7.14%. On last trading day company shares ended up $14.71. Celldex Therapeutics, Inc. (NASDAQ:CLDX) distance from 50-day simple moving average (SMA50) is -34.40%. Analysts mean target price for the company is $36.33.